Full Breakdown
Enveda Secures $311 Million Series E to Accelerate Nature-Derived AI Drug Trials
By Drooid · · How we work
Core Event
Biotech startup Enveda announced a $311 million Series E financing round that values the company at $2 billion. The round was led by Catalio Capital Management with participation from Iconiq and other investors. The new capital doubles Enveda’s valuation compared with the level it held 12 months earlier and is earmarked for advancing AI-identified drug candidates into human clinical studies.
Background: AI-Driven Natural-Product Drug Discovery
Enveda was founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals. The company applies artificial-intelligence models to large libraries of plant and microbial metabolites, aiming to uncover therapeutic molecules that exist in nature rather than synthesizing them de novo. While AI-discovered drugs have yet to receive FDA approval, Enveda is part of a broader wave of firms moving AI-generated candidates toward clinical testing.
Key Figures & Investors
- Viswa Colluru – Founder and CEO; previously at Recursion Pharmaceuticals.
- Catalio Capital Management – Lead investor in the Series E round.
- Iconiq – Participating investor in the financing.
Data & Statistics
- Funding amount: $311 million Series E.
- Post-money valuation: $2 billion, twice the valuation from a year earlier.
- Ongoing clinical programs: at least two candidates, one targeting severe skin conditions and another intended to support weight-loss maintenance after discontinuing GLP-1 therapies.
Official Statements & Responses
Enveda’s leadership described the financing as a catalyst for scaling its AI platform and expanding the pipeline of nature-derived therapeutics. Catalio Capital Management highlighted the company’s unique combination of AI and natural-product chemistry as a differentiator in the biotech landscape. Both parties indicated that the new resources will accelerate the transition of AI-identified molecules into patient trials, underscoring confidence in the approach despite the absence of an FDA-approved AI-discovered drug to date.